2 1 Shi Ji Jing Ji Bao Dao·2025-07-30 09:57Core Viewpoint - WuXi AppTec (药明康德) reported better-than-expected half-year results, leading to a significant increase in its stock price [1] Financial Performance - For the first half of 2025, WuXi AppTec achieved revenue of 20.8 billion yuan, a year-on-year increase of 20.6%, with revenue from continuing operations at 20.41 billion yuan, up 24.2% [2][4] - The company's net profit attributable to shareholders reached 8.56 billion yuan, a remarkable growth of 101.9%, while the adjusted non-IFRS net profit was 6.31 billion yuan, up 44.4% [2] - Based on the growth momentum and order backlog, WuXi AppTec raised its full-year revenue guidance, expecting continuing operations revenue to grow at a rate of 13-17%, up from the previous estimate of 10-15% [2][7] Business Segments - WuXi AppTec's business is divided into four segments: Chemistry, Testing, Biology, and Others [4] - The Chemistry segment reported a revenue increase of 33.5% to 16.30 billion yuan, driven by strong performance in TIDES business, which saw a 141.6% increase in revenue to 5.03 billion yuan [6][7] - The Testing segment experienced a slight decline in revenue by 1.20% to 2.69 billion yuan, while the Biology segment grew by 7.1% to 1.25 billion yuan [7] Order Backlog - As of June 30, 2025, WuXi AppTec's order backlog for continuing operations was 56.69 billion yuan, reflecting a year-on-year growth of 37.2% [3][7] Management Changes - WuXi AppTec announced a management change, with Zhang Yuanzhou resigning as the board secretary, and Han Min appointed as the new board secretary [8][9] - Han Min has over ten years of experience in financial institutions and listed companies, with a background in risk control and corporate governance [9][10]